An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects

Novo Nordisk

Status: Completed

Conditions: Diabetes Mellitus, Type 1; Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin aspart

Study type: Observational

Funder types: Industry

Identifiers

NCT00700648

ANA-3531

Details and patient eligibility

About

This study is conducted in Asia. The aim of this observational study is to evaluate the side effects profile and benefits of using intravenous insulin aspart infusion in hospitalised subjects under normal clinical practice conditions in India.

Enrollment: 3,024 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Any hospitalized subject with hyperglycaemia requiring intravenous insulin therapy is eligible for the study based on the discretion of the physician.

Exclusion criteria

• Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude;
• Subjects with a hypersensitivity to NovoRapid or to any of the excipients.
• Subjects with conditions considered as contraindications.

Trial design

3,024 participants in 1 patient group

A

Treatment:

Drug: insulin aspart